Celltrion's Truxima becomes first Korea-developed biosimilar to lead U.S. market

Korean biopharmaceutical company Celltrion's biosimilar, which is used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.

2026-04-07

Celltrion to cancel 1.7 trillion won in treasury shares to boost shareholder value

Celltrion, a major Korean biopharmaceutical company, said Wednesday it will cancel 1.7 trillion won ($1.1 billion) worth of treasury shares this month as part of efforts to enhance shareholder value.

2026-04-01

Celltrion chairman says firm safe from global instability at shareholder meeting

Seo Jung-jin, chairman of Celltrion Group, returned as chair of the biopharmaceutical's general shareholder meeting for the first time in 11 years on Tuesday, outlining plans to respond to global uncertainties and expand investment.

2026-03-24

Worker dies after fall at Celltrion facility in Incheon

A worker in his 20s fell to his death while carrying out maintenance work at a Celltrion facility in Incheon on Sunday, Incheon authorities said.

2026-03-23

Celltrion secures 294.9 billion won drug deal from global firm

Celltrion has secured a 294.9 billion won contract to supply drugs to a global firm through 2029, potentially rising to 375.4 billion won, amid expanding its CMO business.

2026-03-17

Celltrion to internalize U.S. production with $18B investment in New Jersey facility

Celltrion plans to invest $18 billion over the next decade in its recently acquired U.S. manufacturing facility in Branchburg, New Jersey, expanding production capacity to 132,000 liters (384,871 gallons) to support production.

2026-01-15

Korean biotech firms aim to expand U.S. presence at J.P. Morgan Healthcare Conference

At the 44th J.P. Morgan Healthcare Conference, Korean biotech firms are making efforts to enhance their presence in the U.S. market.

2026-01-13

Celltrion completes acquisition of U.S. biopharmaceutical plant

Celltrion, a major Korean biopharmaceutical company, has completed the acquisition of a manufacturing plant in the United States, the company said Friday, paving the way for local contract manufacturing deals under tariff-free conditions.

2026-01-02

Celltrion to invest 4 trillion won to expand domestic facilities

Celltrion Inc., Korea's leading biopharmaceutical company, said Wednesday it will invest 4 trillion won ($2.7 billion) in the country to expand its domestic facilities amid rising global demand for its products.

2025-11-19

Celltrion report estimates record Q3 operating profit on high-margin drugs

Celltrion Inc., a major Korean biopharmaceutical company, on Tuesday estimated it has achieved a record operating profit in the third quarter on strong sales of high-margin drugs.

2025-10-21

korea joongAng daily